Thymosin α-1 vs KPV.

Thymosin alpha-1 (Tα1, international nonproprietary name thymalfasin; brand name Zadaxin) is a synthetic 28-amino-acid acetylated peptide identical to a naturally occurring fragment derived from prothymosin alpha, a protein produced in the thymus. It belongs to the thymosin family of thymic-derived peptides and is one of the most clinically studied immunomodulatory peptides, marketed as a prescription immune modulator in numerous countries outside the United States.

KPV is a synthetic tripeptide composed of L-lysine, L-proline, and L-valine (Lys-Pro-Val), corresponding to the C-terminal residues 11-13 of alpha-melanocyte-stimulating hormone (alpha-MSH). It is the smallest fragment of alpha-MSH that retains the parent hormone's anti-inflammatory activity, and it is studied as a melanocortin-derived anti-inflammatory agent that lacks the pigmentary (melanogenic) action of the full hormone. It is a research compound, not an approved drug.

Tα1 is an immune modulator rather than a simple immune stimulant: it acts largely through Toll-like receptors, principally TLR2 and TLR9, on dendritic cells, monocytes/macrophages, and other antigen-presenting cells. Downstream MyD88-dependent signaling promotes dendritic cell maturation, biases naive T cells toward Th1 differentiation, augments natural killer cell and cytotoxic T-cell activity, and can modulate regulatory pathways including indoleamine 2,3-dioxygenase. In settings of immune exhaustion or sepsis-associated immunoparalysis, the proposed benefit is restoration of T-lymphocyte numbers and function (e.g., raising depleted CD4+/CD8+ counts and reducing markers of T-cell exhaustion) rather than broad immune activation.

KPV's anti-inflammatory action appears to be largely receptor-independent: rather than signaling primarily through classical melanocortin receptors, it is taken up into intestinal epithelial and immune cells by the proton-coupled di/tripeptide transporter PepT1 (SLC15A1), which is normally restricted to the small intestine but is induced in the colon during inflammation. Once intracellular, KPV dampens canonical pro-inflammatory signaling, notably inhibiting NF-kB and MAP-kinase pathway activation and reducing secretion of pro-inflammatory cytokines. Work dissecting alpha-MSH fragments also implicates antagonism of IL-1beta-driven inflammatory functions as a contributor to its effect. This combination of mechanisms is the basis for its preclinical study in mucosal inflammation.

Human evidence is most developed in chronic hepatitis B and as an adjunct in sepsis, but is mixed and often comes from China-based studies of variable quality. The largest dedicated sepsis trial, ETASS (Wu et al., Critical Care 2013, a multicenter single-blind RCT of 361 patients with severe sepsis), found a reduction in 28-day all-cause mortality that did not reach statistical significance, so its primary endpoint was formally negative; subsequent systematic reviews (e.g., Liu et al., BMC Infect Dis 2016) noted possible mortality benefit but flagged small sample sizes, heterogeneity, and risk of bias. In COVID-19, the widely cited Liu et al. (Clin Infect Dis 2020) report associating Tα1 with lower mortality was a retrospective review of only 76 severe cases, not a randomized trial, and cannot establish efficacy. For hepatitis B, meta-analyses (e.g., entecavir plus Tα1 in HBV-related cirrhosis, BMC Gastroenterol 2020) suggest possible adjunctive benefit on virologic and immune endpoints but again rest on heterogeneous trials; high-quality Western regulatory trials have not confirmed a clear benefit. Much of the broader "immune-restoring" and anti-cancer rationale remains preclinical or mechanistic.

The evidence base for KPV is preclinical (cell culture and rodent models); there are no completed human clinical trials demonstrating efficacy or safety. Dalmasso and colleagues (Gastroenterology, 2008) showed that nanomolar KPV inhibited NF-kB and MAP-kinase activation in human intestinal epithelial (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells via PepT1, and that oral KPV reduced DSS- and TNBS-induced colitis in mice. Kannengiesser et al. (Inflammatory Bowel Diseases, 2008) reported that KPV attenuated disease in DSS and CD45RB-transfer murine colitis models, with effects that did not require functional MC1R, supporting a non-melanocortin-receptor mechanism. Earlier mechanistic dissection by Getting, Schioth, and Perretti (J Pharmacol Exp Ther, 2003) compared core and C-terminal (KPV) alpha-MSH peptides and characterized their anti-inflammatory pharmacology. The broader pharmacology is summarized in a review by Brzoska et al. (Endocrine Reviews, 2008); the gap to human disease remains unbridged.

Across decades of clinical use as thymalfasin, Tα1 has generally been reported as well tolerated, with injection-site reactions among the more commonly noted effects; it is a peptide given by injection in studied settings. Because its action is immunomodulatory, theoretical and context-dependent concerns include effects in autoimmune disease, transplant recipients, or other immune-sensitive populations, and immunogenicity is one reason regulators have scrutinized compounded versions. Importantly, much safety data comes from regulated pharmaceutical product used under medical supervision; the purity, identity, and safety of research-grade or compounded "gray market" material are not assured, and long-term safety outside approved indications is not well characterized.

Documented safety data come almost entirely from cell and rodent studies, where KPV has generally been reported as well tolerated at the doses tested; there is no established human safety profile, no characterized adverse-event spectrum in people, and no pharmacovigilance data. Long-term effects, immunogenicity, effects in pregnancy, and drug interactions are unknown. Because PepT1 expression and KPV uptake are upregulated specifically in inflamed tissue, the cellular pharmacology may differ between healthy and diseased states, which is not characterized in humans. Material sold for research or compounded use is not subject to pharmaceutical-grade quality control, introducing additional purity and identity risks.

Thymalfasin (Zadaxin) is approved and marketed as a prescription drug in roughly 30-plus countries (including China, Italy, and parts of Asia, Latin America, and the Middle East), chiefly for chronic hepatitis B and as an immune adjunct, but it is NOT approved by the US FDA or centrally by the EMA; in the US it has held orphan-drug designations and been studied investigationally. In US compounding, FDA placed thymosin alpha-1 in Category 2 of the interim 503A bulk substances list in 2023 (citing safety/data concerns), and in 2024 it was removed from Category 2 after its nomination was withdrawn, leaving it without a clear compounding pathway.

KPV is not approved by the FDA (or other major regulators) for any indication and has no marketed drug product; it is an investigational/research-use compound. It is not a recognized dietary supplement ingredient, and any human use occurs outside of established regulatory approval.